DIFLUNISAL

Post-LOE

diflunisal

Merck & Co.

ANDAORALTABLET

Approved

Jun 2017

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

DIFLUNISAL (diflunisal) by Merck & Co. is cyclooxygenase inhibitors [moa]. Approved for rheumatoid arthritis. First approved in 2017.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Cyclooxygenase Inhibitors

Pharmacologic Class:

Nonsteroidal Anti-inflammatory Drug

Indications (1)

Rheumatoid arthritis

Clinical Trials (1)

NCT04113668Phase 1Completed

The Effects Diflunisal on the Levels of BMS-986165 in Healthy Participants

Started Oct 2019

48 enrolled

Healthy Participants

Company

Worked on DIFLUNISAL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.